恒瑞医药子公司注射用SHR-1826纳入突破性治疗品种名单

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the National Medical Products Administration's list of breakthrough therapies, targeting a specific type of lung cancer [1] Group 1 - The indication for SHR-1826 is for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer that has c-Met overexpression (2-3+, ≥50%) and has failed at least one line of systemic therapy [1]